Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Statin therapy: does sex matter?

Faubion SS, Kapoor E, Moyer AM, Hodis HN, Miller VM.

Menopause. 2019 Sep 9. doi: 10.1097/GME.0000000000001412. [Epub ahead of print]

PMID:
31513091
2.

Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug.

3.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

4.

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.

Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X.

Cochrane Database Syst Rev. 2018 Nov 19;11:CD012502. doi: 10.1002/14651858.CD012502.pub2.

PMID:
30480766
5.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
6.

Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.

Sanders RD, Nicholson A, Lewis SR, Smith AF, Alderson P.

Cochrane Database Syst Rev. 2013 Jul 3;(7):CD009971. doi: 10.1002/14651858.CD009971.pub2. Review.

PMID:
23824754
7.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
8.

Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Krysiak R, Okopień B, Herman Z.

Drugs. 2003;63(17):1821-54. Review.

PMID:
12921488
9.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Review.

PMID:
24880031
10.

Women Versus Men: Is There Equal Benefit and Safety from Statins?

Plakogiannis R, Arif SA.

Curr Atheroscler Rep. 2016 Feb;18(2):6. doi: 10.1007/s11883-016-0562-9. Review.

PMID:
26782824
11.

Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Wierzbicki AS, Viljoen A.

Drug Saf. 2010 Feb 1;33(2):115-25. doi: 10.2165/11319490-000000000-00000. Review.

PMID:
20082538
12.
13.

Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.

Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E; Ezetimibe Study Group.

J Womens Health (Larchmt). 2004 Dec;13(10):1101-7.

PMID:
15650343
14.

Adding ezetimibe to statin therapy: latest evidence and clinical implications.

Vavlukis M, Vavlukis A.

Drugs Context. 2018 Jul 9;7:212534. doi: 10.7573/dic.212534. eCollection 2018. Review.

15.

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.

Izquierdo-Palomares JM, Fernandez-Tabera JM, Plana MN, Añino Alba A, Gómez Álvarez P, Fernandez-Esteban I, Saiz LC, Martin-Carrillo P, Pinar López Ó.

Cochrane Database Syst Rev. 2016 Nov 26;11:CD009462. Review.

16.

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A.

Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9.

PMID:
25579834
17.

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

Evans M, Rees A.

Drug Saf. 2002;25(9):649-63. Review.

PMID:
12137559
18.

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.

Pedersen TR.

Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000. Review.

PMID:
21391729
19.
20.

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Lennernäs H, Fager G.

Clin Pharmacokinet. 1997 May;32(5):403-25. Review.

PMID:
9160173

Supplemental Content

Support Center